

HUTCHMED (13 HK)

FDA raised the bar for the approval of surufatinib

- FDA requires MRCT for the approval of surufatinib in the US.** The FDA has issued a Complete Response Letter (CRL) regarding the NDA of surufatinib for the treatment of extra-pancreatic and pancreatic neuroendocrine tumors (epNETs and pNETs). FDA decided that the current data package of two China Ph3 trials (SANET-ep and SANET-p) and one bridging study in the US (NCT02549937) does not support approval in the US. FDA requires an MRCT that includes subjects more representative of the US patient population and aligned to US medical practice, while FDA raised no concern on surufatinib's safety profile. Surufatinib received FDA Fast Track Designations in Apr 2020 for the treatment of pNETs and epNETs, and obtained Orphan Drug Designation for pNETs in Nov 2019. Considering the remarkable clinical efficacy of surufatinib demonstrated in the China Ph3 studies in NET, and the limited available therapies for NET in the US, we believe HCM will continue to pursue FDA approvals of surufatinib by conducting additional MRCTs. This FDA action may cause approximately 3-4 years of delay of surufatinib's US approval. Meanwhile, surufatinib's marketing application in the Europe is at the late stage of review, and the drug is undergoing a bridging study to support its application in Japan. We think the registration process of surufatinib in Europe and Japan should not be impacted by that in the US.
- Surufatinib to meet the large unmet need in NET treatment.** Surufatinib showed satisfying safety and potent efficacy for the treatment of NET. For the SANET-ep study, a Ph3 trial in advanced epNET patients in China, median PFS was significantly longer for surufatinib arm at 9.2 months, compared to 3.8 months for placebo arm (HR 0.334; $p < 0.0001$). For the SANET-p study, a Ph3 trial in advanced pNET patients in China, surufatinib achieved a median PFS of 10.9 months vs 3.7 months for placebo (HR 0.491; $p = 0.0011$). In the US phase 1/2 bridging study ([link](#)), surufatinib's mPFS was 11.50 months and 15.18 months for patients with epNETs and pNETs, respectively. Currently, there's limited targeted therapies for NETs in China and the US, mainly sunitinib for pNET and everolimus for pNET and non-functional NET of GI or lung origin. Thus, we see large global market potential for surufatinib as a potent targeted therapy for NET.
- Ongoing MRCTs of other key assets form the basis for HCM's global expansion.** The ongoing global phase 2 SAVANNAH trial of savolitinib for NSCLC and the global phase 3 FRESCO-2 trial of fruquintinib for colorectal cancer are expected to have data read-out within this year, based on which HCM may file applications in the US and other global markets.
- Maintain BUY.** We revised our DCF-based TP from HK\$73.25 to HK\$51.15 based on a 14-year DCF valuation (WACC: 10.47%, terminal growth rate: 3%).

Earnings Summary

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (US\$ mn)	228	356	443	552	841
YoY growth (%)	11	56	24	25	52
Net loss (US\$ mn)	(126)	(195)	(325)	(281)	(111)
EPS (US\$)	(0.18)	(0.25)	(0.38)	(0.33)	(0.13)
Consensus EPS (US\$)	N/A	N/A	(0.45)	(0.42)	(0.25)
R&D expenses (US\$ mn)	(175)	(299)	(330)	(350)	(336)
Capex (US\$ mn)	(8)	(16)	(50)	(15)	(10)

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	HK\$51.15
(Previous TP)	HK\$73.25)
Up/Downside	+141.83%
Current Price	HK\$21.15

China Healthcare Sector

Jill Wu, CFA
 (852) 3900 0842
 jillwu@cmbi.com.hk

Andy Wang
 (852) 3657 6288
 andywang@cmbi.com.hk

Mkt. Cap. (HK\$ mn)	18,285
Avg. 3mths t/o (HK\$ mn)	30.58
52W High/Low (HK\$)	85.80/20.75
Total Issued Shares (mn)	865

Source: Bloomberg

Shareholding Structure

CK Hutchison Holdings	38.46%
The Capital Group	10.79%
JP Morgan	6.21%
Free float	44.54%


Source: HKEx, Bloomberg

Share performance

	Absolute	Relative
1-mth	-13.2%	-9.3%
3-mth	-37.0%	-28.9%
6-mth	-46.3%	-36.1%

Source: Bloomberg

12-mth price performance



Source: Bloomberg

Auditor: PricewaterhouseCoopers
Web-site: <https://www.hutch-med.com>

Related Reports

- Strong sales momentum of three marketed drugs – 7 Mar 2022
- Promising clinical data presented at ESMO Conference – 30 Sep 2021
- A home-grown, global-facing Biopharma – 17 Sep 2021

Figure 1: Risk-adjusted DCF valuation

DCF Valuation (in US\$ mn)	2021A	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	(217)	(330)	(287)	(115)	147	316	517	714	910	1,014	1,077	1,121	1,008	1,031	1,055
Tax rate	-6%	0%	0%	0%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%	15%
EBIT*(1-tax rate)	(229)	(330)	(287)	(115)	125	268	440	607	774	862	916	953	857	876	896
+ D&A	7	8	17	16	15	14	13	13	12	12	11	11	11	11	11
- Change in working capital	33	21	(11)	(24)	(50)	(74)	(58)	(62)	(49)	(39)	(29)	(19)	(4)	32	(7)
- Capex	(16)	(50)	(15)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
FCFF	(206)	(351)	(296)	(133)	80	199	384	548	727	824	888	935	853	908	889
Terminal value	12,265														
Present value of enterprise (US\$ mn)	5,076														
Net debt (US\$ mn)	(630)														
Equity value (US\$ mn)	5,706														
Equity value (HK\$ mn)	44,218														
No. of outstanding shares (mn)	865														
DCF per share (HK\$)	51.15														
Terminal growth rate	3.0%														
WACC	10.47%														
Cost of Equity	13.5%														
Cost of Debt	4.0%														
Equity Beta	1.00														
Risk Free Rate	3.0%														
Market Risk Premium	10.5%														
Target Debt to Asset ratio	30.0%														
Effective Corporate Tax Rate	15.0%														

Source: CMBIGM estimates

Figure 2: Sensitivity analysis (HK\$)

		WACC				
		9.47%	9.97%	10.47%	10.97%	11.47%
Terminal growth rate	4.00%	68.70	61.62	55.67	50.60	46.25
	3.50%	64.94	58.62	53.25	48.62	44.61
	3.00%	61.75	56.05	51.15	46.89	43.17
	2.50%	59.03	53.82	49.31	45.37	41.90
	2.00%	56.66	51.88	47.69	44.01	40.75

Source: CMBIGM estimates

Figure 3: CMBIGM estimates revision

US\$ mn	New			Old			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	443	552	841	454	620	974	-2%	-11%	-14%
Gross Profit	128	199	387	134	240	474	-4%	-17%	-18%
Operating Profit	(330)	(287)	(115)	(326)	(252)	(108)	N/A	N/A	N/A
Net profit	(325)	(281)	(111)	(320)	(247)	(103)	N/A	N/A	N/A
EPS (US\$)	(0.38)	(0.33)	(0.13)	(0.37)	(0.29)	(0.12)	N/A	N/A	N/A
Gross Margin	28.88%	35.96%	46.08%	29.52%	38.71%	52.82%	-0.63 ppt	-2.75 ppt	-6.75 ppt

Source: Company data, Bloomberg, CMBIGM estimates

Figure 4: CMBIGM estimates vs consensus

US\$ mn	CMBIGM			Consensus			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	443	552	841	419	544	804	6%	1%	5%
Gross profit	128	199	387	148	239	415	-13%	-17%	-7%
Operating profit	(330)	(287)	(115)	(392)	(373)	(249)	N/A	N/A	N/A
Net profit	(325)	(281)	(111)	(358)	(320)	(196)	N/A	N/A	N/A
EPS (US\$)	(0.38)	(0.33)	(0.13)	(0.45)	(0.42)	(0.25)	N/A	N/A	N/A
Gross margin	28.88%	35.96%	46.08%	35.24%	44.00%	51.66%	-6.35 ppt	-8.04 ppt	-5.58 ppt

Source: Bloomberg, CMBIGM estimates

Financial Statements

Income statement

YE 31 Dec (US\$ mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue	228	356	443	552	841
COGS	(189)	(258)	(315)	(353)	(453)
Gross profit	39	98	128	199	387
Administrative expenses	(50)	(89)	(75)	(80)	(84)
R&D expenses	(175)	(299)	(330)	(350)	(336)
Selling expenses	(11)	(38)	(53)	(55)	(82)
Operating profit	(197)	(328)	(330)	(287)	(115)
Gain on divestment equity investee	0	121	0	0	0
Interest income	3	2	4	3	3
Other income (expenses), net	5	2	0	0	0
Interest expense	(1)	(1)	(0)	(0)	(0)
Other expense	(0)	(13)	0	0	0
Pre-tax profit	(190)	(216)	(327)	(284)	(113)
Income tax	(5)	(12)	0	0	0
Equity in earnings of equity investees, net of tax	79	61	30	30	30
Minority interests	(10)	(28)	(28)	(28)	(28)
Net profit (loss)	(126)	(195)	(325)	(281)	(111)

Cash flow summary

YE 31 Dec (US\$ mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Profit before tax	(116)	(167)	(297)	(254)	(83)
Depreciation and amortization	6	7	8	17	16
Change in working capital	29	33	21	(11)	(24)
Changes in income tax balances	(1)	7	0	0	0
Others	19	(84)	(30)	(30)	(30)
Net cash from operating activities	(62)	(204)	(298)	(278)	(121)
Capex	(8)	(16)	(50)	(15)	(10)
Net proceeds from disposal of short-term investments	(733)	(1,356)	0	0	0
Other investing activities	615	1,066	300	300	0
Net cash from investing activities	(125)	(306)	250	285	(10)
Net proceeds from shares issued	319	717	0	0	0
Net bank borrowing	0	0	0	0	0
Other financing activities	(23)	(67)	0	0	0
Net cash from financing activities	296	650	0	0	0
FX changes	6	2	0	0	0
Net change in cash	109	139	(48)	7	(131)
Cash at the beginning of the year	121	236	378	330	337
Cash at the end of the year	236	378	330	337	206

Balance sheet

YE 31 Dec (US\$ mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Non-current assets	193	161	232	261	284
PP&E	24	41	83	81	75
Right-of-use assets	8	12	12	12	12
Deferred tax assets	2	9	9	9	9
Investments in equity investees	0	0	0	0	0
Other non-current assets	20	22	22	22	22
Current assets	531	1,212	841	568	467
Cash and cash equivalents	236	378	330	337	206
Short-term investments	200	634	334	34	34
Accounts receivable	48	84	66	82	102
Inventories	20	36	30	34	43
Other current assets	28	81	81	81	81
Current liabilities	158	312	309	318	324
Accounts payable	32	41	39	48	53
Other payables, accruals and advance receipts	121	211	211	211	211
Lease liabilities	3	0	0	0	0
Other current liabilities	(1)	55	31	31	31
Non-current liabilities	47	21	21	21	21
Lease liabilities	6	7	7	7	7
Long-term bank borrowings	27	0	0	0	0
Other non-current liabilities	14	14	14	14	14
Total net assets	519	1,040	743	489	406
Minority interest	35	53	80	108	135
Shareholders' equity	484	987	662	381	271

Key ratios

YE 31 Dec	FY20A	FY21A	FY22E	FY23E	FY24E
Profit & loss ratios (%)					
Gross margin	17	27	29	36	46
EBITDA margin	N/A	N/A	N/A	N/A	N/A
Net margin	N/A	N/A	N/A	N/A	N/A
Effective tax rate (%)	N/A	N/A	N/A	N/A	N/A
Balance sheet ratios					
Current ratio (x)	3	4	3	2	1
Inventory days	35	39	35	35	35
Account receivables turnover days-third parties	70	66	66	66	66
Account receivables turnover days-related parties	2	1	1	1	1
Account payables turnover days	54	51	55	55	55
Total debt to asset ratio (%)	28	24	31	41	46
Returns (%)					
ROE	(22)	(16)	(40)	(52)	(20)
ROA	(16)	(12)	(28)	(31)	(11)
Per share data					
EPS (US\$)	(0.2)	(0.2)	(0.4)	(0.3)	(0.1)
DPS (US\$)	0.0	0.0	0.0	0.0	0.0
BVPS (US\$)	0.7	1.3	0.9	0.6	0.5

Source: Company data, CMBIGM estimates

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIGM

OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.